These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 38801530)

  • 1. Unlocking new avenues for neuropsychiatric disease therapy: the emerging potential of Peroxisome proliferator-activated receptors as promising therapeutic targets.
    Dey AD; Mannan A; Dhiman S; Singh TG
    Psychopharmacology (Berl); 2024 Aug; 241(8):1491-1516. PubMed ID: 38801530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders.
    Nierenberg AA; Ghaznavi SA; Sande Mathias I; Ellard KK; Janos JA; Sylvia LG
    Biol Psychiatry; 2018 May; 83(9):761-769. PubMed ID: 29502862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders.
    Matrisciano F; Pinna G
    Adv Exp Med Biol; 2023; 1411():513-535. PubMed ID: 36949324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
    Menendez-Gutierrez MP; Roszer T; Ricote M
    Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting lipid-sensing nuclear receptors PPAR (α, γ, β/δ): HTVS and molecular docking/dynamics analysis of pharmacological ligands as potential pan-PPAR agonists.
    Mandal SK; Puri S; Kumar BK; Muzaffar-Ur-Rehman M; Sharma PK; Sankaranarayanan M; Deepa PR
    Mol Divers; 2024 Jun; 28(3):1423-1438. PubMed ID: 37280404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptors as therapeutic target for cancer.
    Wang Y; Lei F; Lin Y; Han Y; Yang L; Tan H
    J Cell Mol Med; 2024 Mar; 28(5):e17931. PubMed ID: 37700501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder.
    Barone R; Rizzo R; Tabbì G; Malaguarnera M; Frye RE; Bastin J
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.
    Agarwal S; Yadav A; Chaturvedi RK
    Biochem Biophys Res Commun; 2017 Feb; 483(4):1166-1177. PubMed ID: 27514452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
    Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
    Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.
    Żulińska S; Strosznajder AK; Strosznajder JB
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?
    Tufano M; Pinna G
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32120979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.
    Escandon P; Vasini B; Whelchel AE; Nicholas SE; Matlock HG; Ma JX; Karamichos D
    Exp Eye Res; 2021 Jul; 208():108617. PubMed ID: 34010603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.
    Peters JM; Shah YM; Gonzalez FJ
    Nat Rev Cancer; 2012 Feb; 12(3):181-95. PubMed ID: 22318237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review.
    Rolland B; Deguil J; Jardri R; Cottencin O; Thomas P; Bordet R
    Curr Drug Targets; 2013 Jun; 14(7):724-32. PubMed ID: 23531161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PPARs for therapy of atherosclerosis: A review.
    Miao M; Wang X; Liu T; Li YJ; Yu WQ; Yang TM; Guo SD
    Int J Biol Macromol; 2023 Jul; 242(Pt 2):125008. PubMed ID: 37217063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
    Mirza AZ; Althagafi II; Shamshad H
    Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
    Dixit G; Prabhu A
    Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.